@article{fc27a3ad539c40509328de15412caaf5,
title = "Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials",
abstract = "Patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) with deletion 17p [del(17p)] have poor outcomes with chemoimmunotherapy. Ibrutinib is indicated for the treatment of CLL/SLL, including del(17p) CLL/SLL, and allows for treatment without chemotherapy. This integrated analysis was performed to evaluate outcomes in 230 patients with relapsed/refractory del(17p) CLL/SLL from three ibrutinib studies. With a median of 2 prior therapies (range, 1–12), 18% and 79% of evaluable patients had del(11q) or unmutated IGHV, respectively. With a median follow-up of 28 months, overall response rate was 85% and estimated 30-month progression-free and overall survival rates were 57% [95% confidence interval (CI) 50–64] and 69% (95% CI 61–75), respectively. Patients with normal lactate dehydrogenase or no bulky disease had the most favourable survival outcomes. Sustained haematological improvements in haemoglobin, platelet count and absolute neutrophil count occurred in 61%, 67% and 70% of patients with baseline cytopenias, respectively. New onset severe cytopenias and infections decreased in frequency over time. Progression-free and overall survival with ibrutinib surpass those of other therapies for patients with del(17p) CLL/SLL. These results provide further evidence of the robust clinical activity of ibrutinib in difficult-to-treat CLL/SLL populations.",
keywords = "17p deletion, BTK inhibitor, chronic lymphocytic leukaemia, ibrutinib",
author = "Jeffrey Jones and Anthony Mato and Steven Coutre and Byrd, {John C.} and Furman, {Richard R.} and Peter Hillmen and Anders Osterborg and Constantine Tam and Stephan Stilgenbauer and Wierda, {William G.} and Heerema, {Nyla A.} and Karl Eckert and Fong Clow and Cathy Zhou and Chu, {Alvina D.} and James, {Danelle F.} and O'Brien, {Susan M.}",
note = "Funding Information: JJ: consultancy/advisory role and research funding from Pharmacyclics LLC, an AbbVie Company, AbbVie, and Janssen; AM: consultancy/advisory role with Celgene, Gilead, AbbVie, Janssen, and Pharmacyclics LLC, an Abb-Vie Company, travel accommodations from TG Therapeutics, research funding from TG Therapeutics, Acerta, DTRM, Gilead, AbbVie, and Janssen; SC: consultancy/advisory role for Janssen, Pharmacyclics LLC, an AbbVie Company, research funding from AbbVie and Pharma-cyclics LLC, an AbbVie Company; JCB: research funding from Genentech, Acerta, and Pharmacyclics LLC, an AbbVie Company; RF: honoraria, consultancy/advisory role, speakers{\textquoteright} bureau for Pharmacyclics LLC, an AbbVie Company; PH: honoraria, consultancy/advisory role, and research funding from Roche, GSK, Janssen, Gilead, Abb-Vie, honoraria and research funding from Novartis, Phar-macyclics LLC, an AbbVie Company, research funding from Celgene; AO: honoraria from Gilead and Janssen, research funding from GSK, Janssen, Pharmacyclics LLC, an AbbVie Company, and Gilead; CT: honoraria, consultancy/advisory role, and research funding from Janssen; SS: honoraria and consultancy/advisory role with AbbVie, Amgen, Boehringer-Ingelheim, Celgene, Genentech, Gen-zyme, Gilead, GSK, Janssen, Mundipharma, Novartis, Phar-macyclics LLC, an AbbVie Company, and Hoffmann La-Roche, speakers{\textquoteright} bureau and travel accommodations from AbbVie, Janssen, and Pharmacyclics LLC, an AbbVie Company, research funding from AbbVie, Amgen, Boehringer-Ingelheim, Celgene, Genentech, Genzyme, Gilead, GSK, Janssen, Mundipharma, Novartis, Pharmacyclics LLC, an AbbVie Company, and Hoffman La-Roche; WGW: honoraria from Sanofi, Genentech/Roche, Pharmacyclics LLC, an AbbVie Company, Celgene, Gilead, GSK/Novartis, Gen-zyme, Merck, AbbVie, and Emergent, consulting/advisory role for GSK/Novartis, AbbVie, Genentech, Pharmacyclics LLC, an AbbVie Company, Gilead, Emergent, Sanofi, Cel-gene, Genzyme, and Merck, research funding from GSK/ Novartis, AbbVie, Genentech, Karyopharm, Pharmacyclics, Acerta, Gilead, Janssen, Emergent, Juno, and Kite; KE: employment and patents/royalties/other intellectual property from Pharmacyclics LLC, an AbbVie Company, equity ownership with AbbVie; FC: employment and leadership with Pharmacyclics LLC, an AbbVie Company, equity ownership with AbbVie; CZ, ADC, DFJ: employment with Pharmacyclics, LLC, an AbbVie Company, equity ownership with AbbVie; SOB: consultancy/advisory role with Amgen, Astellas, Celgene GSK, Janssen, Aptose Biosciences, Vaniam Group, AbbVie, Sunesis, Alexion, Gilead, Pharma-cyclics LLC, an AbbVie Company, TG Therapeutics, and Pfizer, research funding from ProNai, Regeneron, Acerta, Gilead Pharmacyclics, TG Therapeutics, and Pfizer, NH: no relevant conflicts of interest to disclose. Publisher Copyright: {\textcopyright} 2018 The Authors. British Journal of Haematology published by John Wiley & Sons Ltd",
year = "2018",
month = aug,
doi = "10.1111/bjh.15421",
language = "English",
volume = "182",
pages = "504--512",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "4",
}